Effect of galectin‐1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma
Cancer Medicine · 2024
DOI: 10.1002/cam4.7113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jiajun Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Sailing Program, National Natural Science Foundation of China, China Urological Oncology Research Fund.
Abstract (Originalsprache)
Background
In renal cell carcinoma (RCC), no clinically available biomarker has been utilized for checkpoint inhibitor immunotherapy (IO) + tyrosine kinase inhibitor (TKI) combinations. Galectin‐1 overexpression is found in tumors, with potential immune‐regulating roles.
Methods
RNA‐sequencing was performed in two cohorts of RCC treated with IO/TKI combination therapy (ZS‐MRCC, JAVELIN‐101). Immunohistochemistry and flow cytometry were performed to investigate immune cell infiltration and function in the tumor microenvironment of RCC. The RECIST criteria were used to define response and progression‐free survival (PFS).
Results
Galectin‐1 expression was elevated in RCC with higher stage ( p < 0.001) and grade ( p < 0.001). Galectin‐1 expression was also elevated in non‐responders of IO/TKI therapy ( p = 0.047). High galectin‐1 was related with shorter PFS in both ZS‐MRCC cohort ( p = 0.036) and JAVELIN‐101 cohort ( p = 0.005). Multivariate Cox analysis defined galectin‐1 as an independent factor for PFS (HR 2.505; 95% CI 1.116–5.622; p = 0.026). In the tumor microenvironment, high galectin‐1 was related with decreased GZMB+CD8+ T cells (Speraman's ρ = −0.31, p = 0.05), and increased PD1 + CD8+ T cells (Speraman's ρ = 0.40, p = 0.01). Besides, elevated number of regulatory T cells ( p = 0.039) and fibroblasts ( p = 0.011) was also found in high galectin‐1 tumors. Finally, a random‐forest score (RFscore) was built for predicting IO/TKI benefit. IO/TKI therapy showed benefit only in low‐RFscore patients (HR 0.489, 95% CI 0.358–0.669, p < 0.001), rather than high‐RFscore patients (HR 0.875, 95% CI 0.658–1.163, p = 0.357).
Conclusions
High galectin‐1 indicated therapeutic resistance and shorter PFS of IO/TKI therapy. High galectin‐1 also indicated CD8+ T cell dysfunction. High galectin‐1 could be applied for patient selection of IO/TKI therapy in RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Jiajun Wang, Xianglai Xu, Jianming Guo
Förderung
- Shanghai Sailing Program
- National Natural Science Foundation of China
- China Urological Oncology Research Fund
- Shanghai Municipal Health Commission
Zitieren
APA
Wang, J., Zhang, S., Wang, Y., Zhu, Y., Xu, X., & Guo, J. (2024). Effect of galectin‐1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.7113
Vancouver
Wang J, Zhang S, Wang Y, Zhu Y, Xu X, Guo J. Effect of galectin‐1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma. Cancer Medicine. 2024. doi:10.1002/cam4.7113
BibTeX
@article{Wang2024,
author = {Wang, Jiajun and Zhang, Sihong and Wang, Ying and Zhu, Yanjun and Xu, Xianglai and Guo, Jianming},
title = {Effect of galectin‐1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7113}
}
EUVIMED